Human OCIL/CLEC2d PE-conjugated Antibody Summary
Ser57-Val191
Accession # Q9UHP7
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of OCIL/CLEC2d in Raji Human Cell Line by Flow Cytometry. Raji human Burkitt's lymphoma cell line was stained with Mouse Anti-Human OCIL/CLEC2d PE-conjugated Monoclonal Antibody (Catalog # FAB3480P, filled histogram) or isotype control antibody (Catalog # IC002P, open histogram). View our protocol for Staining Membrane-associated Proteins.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: OCIL/CLEC2d
Human OCIL (Osteoclast Inhibitory Lectin), also known as LLT1 and CLEC-2D, is a member of the NK cell receptor group of the C-type lectin superfamily. It is a type II transmembrane protein 191 amino acids (aa) in length that contains a C-terminal 132 aa extracellular domain (ECD). Within the ECD lies a C-type lectin domain (aa 75-186). There are at least two alternate splice forms of OCIL. Both exhibit splicing in the ECD. One shows a 40 aa substitution for the C-terminal 37 amino acids. A second shows a 3 aa substitution for the C-terminal 72 amino acids. The ECD of human OCIL is 49% and 50% aa identical to the ECD in mouse and rat OCIL ECD, respectively. The molecule is found on hematopoietic cells, osteoblasts and chondrocytes. It binds sulfated GAGs and NKR-P1B and D receptors, and blocks osteoclast formation.
Product Datasheets
Citations for Human OCIL/CLEC2d PE-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
5
Citations: Showing 1 - 5
Filter your results:
Filter by:
-
Expression of Lectin-Like Transcript 1, the Ligand for CD161, in Rheumatoid Arthritis.
Authors: Chalan P, Bijzet J, Huitema M, Kroesen B, Brouwer E, Boots A
PLoS ONE, 2015-07-06;10(7):e0132436.
-
CD8+ T cell–Dependent Remodeling of the Tumor Microenvironment Overcomes Chemoresistance
Authors: Liyan Lao, Wenfeng Zeng, Penghan Huang, Huiping Chen, Zishuo Jia, Pei Wang et al.
Cancer Immunology Research
-
Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.
Authors: Marrufo A, Mathew S, Chaudhary P, Malaer J, Vishwanatha J, Mathew P
Am J Cancer Res, 2018-06-01;8(6):1050-1063.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry, ICC -
Human Herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during the course of asymptomatic infection and Kaposi sarcoma.
Authors: Dupuy S, Lambert M, Zucman D, Choukem SP, Tognarelli S, Pages C, Lebbe C, Caillat-Zucman S
PLoS Pathog., 2012-01-12;8(1):e1002486.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
New insights into the phenotype of human dendritic cell populations.
Authors: Clark GJ et al.
Clin Transl Immunology
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human OCIL/CLEC2d PE-conjugated Antibody
Average Rating: 5 (Based on 1 Review)
Have you used Human OCIL/CLEC2d PE-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
